Entera Bio (NASDAQ: ENTX) has announced the presentation of a poster highlighting pharmacokinetic data relating to its first-in-class oral GLP-2 analog program for the treatment of short bowel syndrome (SBS), at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress in Prague, Czech Republic.
According to Entera, the company entered into a research collaboration with OPKO Health (NASDAQ: OPK), in 2023 to develop oral peptide candidates for intestinal malabsorption syndromes, combining OPKO’s proprietary long-acting GLP-2 analog (OPK-8801003) with Entera’s N-Tab oral peptide platform. Currently, the only approved GLP-2 therapy is Gattex (teduglutide), which generates approximately $800 million in annual sales despite requiring daily subcutaneous injections with challenging compliance rates and limited patient access.
In a statement, Miranda Toledano, CEO of Entera, commented, “The pharmacokinetic data presented at ESPEN represent a significant milestone in our journey to develop the first oral GLP-2 therapy and an incremental milestone in validating our N-Tab oral peptide platform. Given the robust oral bioavailability demonstrated in our preclinical studies, we believe this daily GLP-2 tablet candidate could fundamentally change how SBS patients are treated, offering a less-invasive administration that can be titrated to enable personalized dosing in this rare and heterogeneous condition.”
